Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.
about
Pharmacokinetic drug interaction profiles of proton pump inhibitors: an updateA Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitorsMethotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature.The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritisNon-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort studyDetection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media.Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bedPreventing and Managing Toxicities of High-Dose MethotrexateThe Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels.Practical issues with high dose methotrexate therapy.Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Delayed elimination of methotrexate by cola beverages in a pediatric acute lymphoblastic leukemia population.Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?Esomeprazole-induced irritability.Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.Cutaneous toxicity of oral low-dose methotrexate.
P2860
Q27022254-841B5597-12C6-4302-B4E4-B6F4E8DD57D4Q33441225-8BF626CA-709F-4820-98C7-F40D0FDD764AQ34571060-6C6896EF-231F-469A-BB60-2C1531560453Q34642567-AB24D4CF-9DCE-4F14-BE33-C183C73EAC34Q35741946-416AD768-B91A-48B6-A201-21827A4F40D1Q36269700-06D9D1BB-A5A0-4C7B-A588-526AEE8DEDA0Q36320218-A2E36236-7A6A-4733-9EDE-C0BC21993AE2Q36900535-B228BB1A-041A-40BC-BF1B-59555CD2EF9EQ37273398-C450AD2C-BD52-4A82-B226-758BAEC4EB40Q37496637-ECDB0CA9-CA9D-4ADB-A3A7-08BD95B7EDE8Q37709906-66FC5AC2-CBC3-4282-891E-735C0892120CQ38074715-6D8DC0AD-A054-45C0-9AF3-16A2C16DA65EQ38243780-AA1C0543-3972-4A30-AC21-40D26AF75136Q39911676-C41C1D35-D40B-489D-A689-54C4F66B6E8AQ41706384-3150FC49-E1BE-4DF7-94EC-DB6CBC370725Q43715590-AC9B2F1F-287D-4D7A-820A-7606A26B13FBQ47883922-BD1603A7-0C93-491C-AD69-09A373FE2935Q47986834-BA9CBD33-D767-4759-BE9A-4210D9EC9F24Q48249474-4FB16BF1-01FD-4C82-A5D4-D61A3D70968BQ55313980-D55CCB17-13BA-43FD-99D8-83FAD83C40F2
P2860
Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@ast
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@en
type
label
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@ast
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@en
prefLabel
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@ast
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@en
P2093
P2860
P1433
P1476
Accumulating evidence for a dr ...... te and proton pump inhibitors.
@en
P2093
Ann Corken Mackey
Dilara Jappar
Joyce Korvick
Paul Kluetz
Shewit Bezabeh
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0431
P577
2012-04-03T00:00:00Z